MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    The Efficacy and Safety of Gocovri Based on Age: Special Population Analyses of a Phase 3 Study Program

    R. Pahwa, C. Tanner, L. Zhang, R. Johnson, C. Leroue, R. Patni (Kansas City, KS, USA)

    Objective: To assess patient outcomes and adverse events in Parkinson’s disease (PD) patients treated with Gocovri® (amantadine) extended release capsules at bedtime for dyskinesia, by…
  • 2019 International Congress

    Motor assessments in HD clinical trials: Q-Motor versus the UHDRS-TMS – what did we learn from recent studies?

    R. Reilmann, R. Schubert, P. Barallon, P. Pracht, B. Habbel (Muenster, Germany)

    Objective: To review the performance of UHDRS-TMS and Q-Motor quantitative motor measures in recent placebo-controlled clinical trials. Background: The UHDRS-TMS has widely been used to…
  • 2019 International Congress

    Parkinson’s disease and intermittent hypoxia training: beneficial or harmful?

    M. Sharifi-Bonab, J. Sesink, B. Bloem, D. Devos, J. Deguil, C. Moreau (Nijmegen, Netherlands)

    Objective: To systematically review the scientific evidence for beneficial or harmful effects of intermittent hypoxia that were used in Parkinson’s disease (PD) in clinical and…
  • 2019 International Congress

    Asymmetry of motor symptoms in patients with Parkinson’s Disease

    Y. Trufanov, N. Svyrydova, V. Svistun, I. Harkava, H. Bondarenko, N. Zhhilova (Kyiv, Ukraine)

    Objective: The objective of our research was to investigate the asymmetry of motor symptoms in patients with Parkinson’s Disease (PD). Background: In most PD cases…
  • 2019 International Congress

    Ataxia by Mutation in CACNA1A Gene – Case Series

    P. Almeida, J. Pedroso, I. Brandi (Salvador, Brazil)

    Objective: The present study aim to describes 4 patients of the same family with ataxia and migraine. In 2 of them sequencing analysis was positive…
  • 2019 International Congress

    Huntington’s Disease presenting as sporadic cerebellar ataxia

    GLF. Franklin, FAN. Nascimento, GMP. Pavanelli, SSM. Milano, HAT. Teive, NSL. Lima, SR. Raskin (Curitiba, Brazil)

    Objective: To describe a unique case of a woman who presented as a progressive cerebellar ataxia, with no family history of neurological diseases, that after…
  • 2019 International Congress

    Cardiac involvement in AVED

    S. Lucas-Delpozo, D. Moreno-Martínez, M. Tejero-Ambrosio, J. Hernández-Vara (Barcelona, Spain)

    Objective: Case report Background: Ataxia with vitamin E deficiency (AVED) is an autosomal recessive disorder caused by mutations in the gene encoding the α-tocopherol transport…
  • 2019 International Congress

    A Robust and Rapid Method of PCR amplification To Confirm Triplet Repeat Disorders: Single-Step Blood Direct PCR

    I. Singh, V. Swarup, S. Shakya, V. Goyal, A. Srivastava (New Delhi, India)

    Objective: To develop a rapid, robust and more reliable method for an expeditious genetic investigation of patients with TRDs.to develop a rapid, robust and more…
  • 2019 International Congress

    A life-threatening case of Anti-IgLON5 disease

    M. Filidei, N. Tambasco, F. Paolini Paoletti, S. Simoni, E. Brahimi, G. Cappelletti, P. Nigro, P. Calabresi (Perugia, Italy)

    Objective: To present a case of anti-IgLON5 disease with life-threatening respiratory complications. Background: Anti-IgLON5 disease is a little known CNS disorder characterized by non-REM and…
  • 2019 International Congress

    Acute hypertensive crisis with myoclonic movements induced by withdrawal of intrathecal combined clonidine and morphine administration

    A. Saryyeva, J. Krauss, L. Cassini Ascencao (Hannover, Germany)

    Objective: Clonidine is a centrally acting alpha(2)-agonist antihypertensive drug used for opioid/alcohol withdrawal and for intrathecal administration in the treatment of chronic neuropathic pain. Cases…
  • « Previous Page
  • 1
  • …
  • 171
  • 172
  • 173
  • 174
  • 175
  • …
  • 217
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley